This HTML5 document contains 108 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/AHFS/
n10http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00408/identifier/pharmgkb/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00408/identifier/wikipedia/
n12http://linked.opendata.cz/resource/drugbank/dosage/
n30http://linked.opendata.cz/resource/drugbank/drug/DB00408/identifier/bindingdb/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00408/identifier/kegg-compound/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00408/identifier/pubchem-compound/
n29http://bio2rdf.org/drugbank:
n18http://linked.opendata.cz/resource/drugbank/drug/DB00408/identifier/kegg-drug/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00408/identifier/pubchem-substance/
admshttp://www.w3.org/ns/adms#
n31http://linked.opendata.cz/resource/drugbank/drug/DB00408/identifier/drugbank/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00408/identifier/iuphar/
n26http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00408/identifier/guide-to-pharmacology/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://linked.opendata.cz/resource/drugbank/medicinal-product/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00408/identifier/national-drug-code-directory/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n9http://www.drugs.com/cdi/
n27http://www.rxlist.com/cgi/generic2/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n7http://linked.opendata.cz/resource/drugbank/drug/DB00408/identifier/chemspider/
n13http://linked.opendata.cz/ontology/sukl/drug/
n14http://linked.opendata.cz/resource/atc/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00408/identifier/chebi/

Statements

Subject Item
n2:DB00408
rdf:type
n3:Drug
n3:description
An antipsychotic agent used in schizophrenia. [PubChem]
n3:dosage
n12:271B45CA-363D-11E5-9242-09173F13E4C5 n12:271B45C6-363D-11E5-9242-09173F13E4C5 n12:271B45C7-363D-11E5-9242-09173F13E4C5 n12:271B45C8-363D-11E5-9242-09173F13E4C5 n12:271B45C9-363D-11E5-9242-09173F13E4C5 n12:271B45C2-363D-11E5-9242-09173F13E4C5 n12:271B45C3-363D-11E5-9242-09173F13E4C5 n12:271B45C4-363D-11E5-9242-09173F13E4C5 n12:271B45C5-363D-11E5-9242-09173F13E4C5 n12:271B45CC-363D-11E5-9242-09173F13E4C5 n12:271B45CB-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Glazer WM: Does loxapine have "atypical" properties? Clinical evidence. J Clin Psychiatry. 1999;60 Suppl 10:42-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10340686 # Cheung SW, Tang SW, Remington G: Simultaneous quantitation of loxapine, amoxapine and their 7- and 8-hydroxy metabolites in plasma by high-performance liquid chromatography. J Chromatogr. 1991 Mar 8;564(1):213-21. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1860915
n3:group
approved
n3:halfLife
Oral-4 hours
n3:indication
For the management of the manifestations of psychotic disorders such as schizophrenia
n3:manufacturer
n10:271B45B1-363D-11E5-9242-09173F13E4C5 n10:271B45B2-363D-11E5-9242-09173F13E4C5 n10:271B45B0-363D-11E5-9242-09173F13E4C5
owl:sameAs
n26:DB00408 n29:DB00408
dcterms:title
Loxapine
adms:identifier
n6:50841 n7:3827 n16:Loxapine n17:C07104 n18:D02340 n19:205 n20:205 n21:3964 n22:46505047 n23:0378-7005-01 n24:PA450273 n30:22871 n31:DB00408
n3:mechanismOfAction
Loxapine is a dopamine antagonist, and also a serotonin 5-HT2 blocker. The exact mode of action of Loxapine has not been established, however changes in the level of excitability of subcortical inhibitory areas have been observed in several animal species in association with such manifestations of tranquilization as calming effects and suppression of aggressive behavior.
n3:packager
n10:271B45AD-363D-11E5-9242-09173F13E4C5 n10:271B45A8-363D-11E5-9242-09173F13E4C5 n10:271B45AC-363D-11E5-9242-09173F13E4C5 n10:271B45A6-363D-11E5-9242-09173F13E4C5 n10:271B45A7-363D-11E5-9242-09173F13E4C5 n10:271B45A5-363D-11E5-9242-09173F13E4C5 n10:271B45AB-363D-11E5-9242-09173F13E4C5 n10:271B45AE-363D-11E5-9242-09173F13E4C5 n10:271B45A9-363D-11E5-9242-09173F13E4C5 n10:271B45AA-363D-11E5-9242-09173F13E4C5 n10:271B45AF-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Metabolites are excreted in the urine in the form of conjugates and in the feces unconjugated.
n3:synonym
Cloxazepine Loxapine Loxapina 2-Chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine Loxapinum oxilapine
n3:toxicity
LD<sub>50</sub>=65 mg/kg (Orally in mice)
n13:hasAHFSCode
n15:28-16-08-92
n3:foodInteraction
Take with food to reduce irritation. Avoid alcohol.
n3:synthesisReference
U.S. Patents 3,412,193; 3,546,226.
foaf:page
n9:loxapine.html n27:loxapineoc.htm
n3:IUPAC-Name
n4:271B45D1-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B45D7-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B45D6-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B45D3-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B45D4-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B45D5-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B45CF-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B45CD-363D-11E5-9242-09173F13E4C5 n4:271B45D0-363D-11E5-9242-09173F13E4C5 n4:271B45E7-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B45CE-363D-11E5-9242-09173F13E4C5
n13:hasATCCode
n14:N05AH01
n3:H-Bond-Acceptor-Count
n4:271B45DD-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B45DE-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B45D8-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B45D9-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B45DB-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B45DA-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B45DC-363D-11E5-9242-09173F13E4C5
n3:absorption
Systemic bioavailability of the parent drug was only about one third that after an equivalent intramuscular dose (25 mg base) in male volunteers
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
1977-10-2
n3:category
n3:containedIn
n11:271B45B9-363D-11E5-9242-09173F13E4C5 n11:271B45BA-363D-11E5-9242-09173F13E4C5 n11:271B45B7-363D-11E5-9242-09173F13E4C5 n11:271B45B8-363D-11E5-9242-09173F13E4C5 n11:271B45B5-363D-11E5-9242-09173F13E4C5 n11:271B45B6-363D-11E5-9242-09173F13E4C5 n11:271B45B3-363D-11E5-9242-09173F13E4C5 n11:271B45B4-363D-11E5-9242-09173F13E4C5 n11:271B45C1-363D-11E5-9242-09173F13E4C5 n11:271B45BF-363D-11E5-9242-09173F13E4C5 n11:271B45C0-363D-11E5-9242-09173F13E4C5 n11:271B45BD-363D-11E5-9242-09173F13E4C5 n11:271B45BE-363D-11E5-9242-09173F13E4C5 n11:271B45BB-363D-11E5-9242-09173F13E4C5 n11:271B45BC-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B45E2-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B45E4-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B45E5-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B45E6-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B45E1-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B45E0-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B45E3-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B45D2-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B45DF-363D-11E5-9242-09173F13E4C5